You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Gemox chemotherapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type, Early-stage, High-Risk Cancer Trial in Beijing (Anti-PD-1 mAb,

Recruiting
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • +2 more
  • Anti-PD-1 monoclonal antibody
  • +4 more
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
Feb 23, 2022

Cholangiocarcinoma, Intrahepatic Trial in Shanghai (Lenvatinib combined with gemox, Toripalimab combined with lenvatinib)

Active, not recruiting
  • Cholangiocarcinoma, Intrahepatic
  • Lenvatinib combined with gemox
  • Toripalimab combined with lenvatinib
  • Shanghai, China
  • +1 more
Jul 5, 2021

Advanced Primary Liver Cancer, Advanced Biliary Tract Carcinoma Trial in Zhengzhou, Nanjing (SHR-1210, Apatinib, FOLFOX4)

Active, not recruiting
  • Advanced Primary Liver Cancer
  • Advanced Biliary Tract Carcinoma
  • SHR-1210
  • +3 more
  • Zhengzhou, Henan, China
  • +1 more
Apr 26, 2022

Gallbladder Cancer Trial in Varanasi (Everolimus 10 mg, Standard of care)

Recruiting
  • Gallbladder Cancer
  • Everolimus 10 mg
  • Standard of care
  • Varanasi, UP, India
    Banaras Hindu University
Apr 18, 2023

Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib Trial in Shanghai (Neoadjuvant treatment)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • +3 more
  • Neoadjuvant treatment
  • Shanghai, Shanghai, China
    Zhongshan hospital
Jul 5, 2021

Cholangiocarcinoma, Intrahepatic Trial in Shanghai (neoadjuvant treatment)

Recruiting
  • Cholangiocarcinoma, Intrahepatic
  • neoadjuvant treatment
  • Shanghai, Shanghai, China
    Zhongshan hospital
Aug 7, 2020

Combined Hepatocellular Cholangiocarcinoma Trial (gemcitabine ,oxaliplatin,anlotinib,Sintilimab)

Not yet recruiting
  • Combined Hepatocellular Cholangiocarcinoma
  • gemcitabine ,oxaliplatin,anlotinib,Sintilimab
  • (no location specified)
Sep 10, 2023

Gallbladder Carcinoma Trial in Shanghai (gemcitabine and oxaliplatin., Afatinib)

Recruiting
  • Gallbladder Carcinoma
  • Shanghai, Shanghai, China
  • +1 more
Dec 21, 2022

Intrahepatic Cholangiocarcinoma Recurrent Trial (Neoadjuvant chemo)

Not yet recruiting
  • Intrahepatic Cholangiocarcinoma Recurrent
  • Neoadjuvant chemotherapy
  • (no location specified)
Aug 19, 2020

Unresectable Gallbladder Cancer Trial in Guangzhou (Carrilizumab plus GEMOX)

Not yet recruiting
  • Unresectable Gallbladder Cancer
  • Carrilizumab plus GEMOX
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Jun 16, 2023

Biliary Tract Carcinoma Trial in Shanghai (Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab)

Recruiting
  • Biliary Tract Carcinoma
  • Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Dec 25, 2022

Biliary Tract Cancer, PD-1 Antibody, Gemox Trial in Shanghai (PD-1+Lenvatinib+GEMOX)

Recruiting
  • Biliary Tract Cancer
  • +3 more
  • Shanghai, China
    Zhongshan hospital
Dec 11, 2021

Perihilar Cholangiocarcinoma Trial in Guangzhou (PD-1antibody plus GEMOX)

Not yet recruiting
  • Perihilar Cholangiocarcinoma
  • PD-1antibody plus GEMOX
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Jul 31, 2022

Non Hodgkin Lymphoma Trial in Australia, United Kingdom, United States (Magrolimab, Rituximab, Gemcitabine)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • Birmingham, Alabama
  • +19 more
Dec 8, 2022

DLBCL Trial in Worldwide (Polatuzumab Vedotin, Rituximab, Gemcitabine)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Polatuzumab Vedotin
  • +3 more
  • Hollywood, Florida
  • +89 more
Jan 31, 2023

Intrahepatic Cholangiocarcinoma Trial in Shanghai (Gemox combimed PD1 antibody)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Gemox combimed PD1 antibody
  • Shanghai, Shanghai, China
    Zhongshan hospital
Jul 7, 2021

DLBCL, Not Otherwise Specified Trial in Chongqing (selinexor)

Recruiting
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Chongqing, Chongqing, China
    Chongqing University Cancer Hospital
Mar 27, 2023

Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Colorectal Cancer Trial run by the National Cancer

Recruiting
  • Metastatic Colorectal Cancer (Mcrc)
  • +7 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Biliary Tract Cancer, Cholangiocarcinoma Trial in Nanjing (SHR-1210+GEMOX)

Completed
  • Biliary Tract Cancer
  • Cholangiocarcinoma
  • Nanjing, Jiangsu, China
    Jiangsu Province Hospital
Oct 27, 2021

Intrahepatic Cholangiocarcinoma Trial in Shanghai (Toripalimab, Lenvatinib mesylate capsules, Placebo IV)

Not yet recruiting
  • Intrahepatic Cholangiocarcinoma
  • Shanghai, Shanghai, China
    Zhongshan Hospital affiliated to Fudan University
Aug 12, 2022

Digestive Cancer Trial in Montpellier (Regorafenib, GEMOX)

Completed
  • Digestive Cancer
  • Montpellier, France
    Centre Val d'Aurelle
Jan 7, 2020

Potentially Resectable Locally Advanced Malignant Tumors of Biliary System Trial (Tislelizumab)

Not yet recruiting
  • Potentially Resectable Locally Advanced Malignant Tumors of Biliary System
  • (no location specified)
Sep 6, 2021

Neuroendocrine Tumors Trial in France (Oxaliplatin-based chemo, Alkylating-based chemo)

Active, not recruiting
  • Neuroendocrine Tumors
  • Oxaliplatin-based chemotherapy
  • Alkylating-based chemotherapy
  • Amiens, France
  • +18 more
Mar 15, 2022

Cholangiocarcinoma, Intrahepatic Trial in Shanghai (combined therapy using oxaliplatin and gemcitabine chemo, Lenvatinib and PD1

Active, not recruiting
  • Cholangiocarcinoma, Intrahepatic
  • combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)
  • Shanghai, Shanghai, China
    Zhongshan Hospital
Jul 5, 2021

Pancreatic Cancer Trial (Albumin-bound paclitaxel, S-1, Oxaliplatin)

Unknown status
  • Pancreatic Cancer
  • Albumin-bound paclitaxel
  • +3 more
  • (no location specified)
Jan 30, 2019